Literature DB >> 3756066

Quantitative assessment of caffeine partial clearances in man.

A Lelo, J O Miners, R A Robson, D J Birkett.   

Abstract

Five subjects who participated in an earlier study (Lelo et al., 1986b) of the comparative pharmacokinetics of caffeine (CA) and its primary monodemethylated metabolites paraxanthine (PX), theobromine (TB) and theophylline (TP) were administered CA to steady-state. Using areas under the plasma concentration-time curves for each of the dimethylxanthines derived from CA in the steady-state study and individual plasma clearances of PX, TB and TP determined in the previous study, the fractional conversion of CA to PX, TB and TP and the individual partial clearances of CA have been defined. The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively. When only demethylation pathways are considered PX, TB and TP accounted for 83.9 +/- 5.4%, 12.1 +/- 4.1% and 4.0 +/- 1.4%, respectively of the CA demethylations. The mean partial clearance of CA to PX was approximately 8-fold and 23-fold greater than those to TB and TP respectively. These data confirm earlier reports that PX is the major metabolite of CA in humans but suggest that PX formation is quantitatively more important than previously believed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3756066      PMCID: PMC1401107          DOI: 10.1111/j.1365-2125.1986.tb05247.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  A study of the metabolism of theobromine, theophylline, and caffeine in man.

Authors:  H H CORNISH; A A CHRISTMAN
Journal:  J Biol Chem       Date:  1957-09       Impact factor: 5.157

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  The absolute bioavailability of caffeine in man.

Authors:  J Blanchard; S J Sawers
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Drug metabolite kinetics.

Authors:  J B Houston
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

5.  Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration.

Authors:  M M Callahan; R S Robertson; M J Arnaud; A R Branfman; M F McComish; D W Yesair
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

6.  Studies on theobromine disposition in normal subjects. Alterations induced by dietary abstention from or exposure to methylxanthines.

Authors:  D D Drouillard; E S Vesell; B H Dvorchik
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

7.  A simple test for acetylator phenotype using caffeine.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

8.  Comparative pharmacokinetics of caffeine in young and elderly men.

Authors:  J Blanchard; S J Sawers
Journal:  J Pharmacokinet Biopharm       Date:  1983-04

9.  Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines.

Authors:  A Lelo; J O Miners; R Robson; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

10.  The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers.

Authors:  A N Kotake; D A Schoeller; G H Lambert; A L Baker; D D Schaffer; H Josephs
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

View more
  21 in total

1.  Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation.

Authors:  Jack E James; Peter J Rogers
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

Review 2.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

3.  Self-report reliability and symptomatology of habitual caffeine consumption.

Authors:  J E James; M S Bruce; M H Lader; N R Scott
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 4.  International society of sports nutrition position stand: caffeine and exercise performance.

Authors:  Nanci S Guest; Trisha A VanDusseldorp; Michael T Nelson; Jozo Grgic; Brad J Schoenfeld; Nathaniel D M Jenkins; Shawn M Arent; Jose Antonio; Jeffrey R Stout; Eric T Trexler; Abbie E Smith-Ryan; Erica R Goldstein; Douglas S Kalman; Bill I Campbell
Journal:  J Int Soc Sports Nutr       Date:  2021-01-02       Impact factor: 5.150

Review 5.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

6.  Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.

Authors:  L J Notarianni; S E Oliver; P Dobrocky; P N Bennett; B W Silverman
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

7.  Interaction between oral ciprofloxacin and caffeine in normal volunteers.

Authors:  D P Healy; R E Polk; L Kanawati; D T Rock; M L Mooney
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity.

Authors:  Dimiter Terziivanov; Kristina Bozhinova; Velislava Dimitrova; Ivanka Atanasova
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

10.  Urinary caffeine metabolites in man. Age-dependent changes and pattern in various clinical situations.

Authors:  D Ullrich; D Compagnone; B Münch; A Brandes; H Hille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.